A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myelomaJuan Du, Jia Liu, Haiyan He et al.|Blood|2025Cited by 3
P-136 Phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myelomaJuan Du, Wei Cao, Wanting Qiang et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 0